Drugs in gout epidemiology Male to female ration 10:1 Prevalence of hyperuricemia 5% Prevalence of gout 0.2%

Slides:



Advertisements
Similar presentations
GOUT Disease caused by tissue deposition of Monosodium urate crystals as a result of supersatuaration of extra cellular fluid with MSU.
Advertisements

N ON - STEROIDAL ANTI - INFLAMMATORY DRUGS. BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF.
TXF Caveat on urate levels Serum uric acid level may be normal at the time of an acute attack. Normal level does not rule out gout. May be better.
Prepared by : Tamara Odeh Diana Jawhari Supervised by : Dr. Ola Ayesh.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 74 Drug Therapy of Gout.
Gout & hyperuricemia.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
Gout: Its not all crystal clear Robert L. Wortmann, M.D. Department of Internal Medicine The University of Oklahoma College of Medicine, Tulsa.
PHCL 424 Management Gout Ahmed Shaman Clinical Pharmacy Department KSU 1.
Reginald D Sanders, MD LSU Clinical Pharmacology Drug Therapy of Gout.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
GOUT. Gout is a familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate crystals. The metatarsophalangeal.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Chapter 13 Agents Used to Treat Hyperuricemia and Gout.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Anti-Inflammatory & Immunosuppressive Drugs 2
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
GOUT TREATMENT. Gout prevalence doubled over the last 20 yrs. Factors? - longevity - diuretic use - low dose ASA - obesity - end stage renal disease -
Drug therapy of gout - overview what is gout? what happens to patients with gout & why? what drugs are available for managing gout? how are those drugs.
N ON - STEROIDAL ANTI - INFLAMMATORY DRUGS. OBJECTIVES At the end of the lecture the students should : Define NSAIDs Describe the classification of this.
Propionic acid derivatives Ibuprofen, naproxen, fenoprofen, flurbiprofen, oxaprozin,→ anti-inflammatory, analgesic, and antipyretic.  These drugs are.
GOUT.
Drug Therapy of Gout.
Clinical Case #6 By Chen, chun-Yu (Kim) Chen, I -chun (Afra) Chen, I -chun (Afra)
Summary Lecture Gout/Glaucoma Learning Outcomes Predict the activity of a drug based on its structure & physiochemical properties Demonstrate an understanding.
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 20 Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs.
Slow Acting Anti-inflammatory Drugs ). BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSF.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Agents Used to Treat Hyperuricemia and Gout
Drug Therapy of Gout. Drug therapy of gout What Is Gout?
Gout Treatment Megan Chan, PGY-2 UHCMC Gout Acute gouty arthritis = monosodium urate crystals in synovial fluid leukocytes – Serum urate ≥ 6.8 =
Manufacturer: AstraZeneca FDA Approval Date: December 22, 2015
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Colchicine: Colchicine: Effective & specific gout Rx, but less favored than NSAIDs because of slow onset of action & high incidence of side effects. Effective.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Non-steroidal anti-inflammatory drugs
Gout Pharmacotherapies Joseph Kitzmiller MD PhD FCP 5086 Graves Hall Assistant Professor – Biological Chemistry & Pharmacology
ANTI-GOUT DRUGS. GOUT A familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate in joints.
Purine Degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Gout Ashley Guzman Primary Care I: Acute and Chronic Health Problems
OBJECTIVES and METHODOLOGY
Gout Asad Khan Consultant Rheumatologist
Gout Is recurrent inflammatory disorder characterized by
Gout.
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Introduction to pathology
Drugs in gout.
GOUTY ARHTRITIS.
ليس العار في أن نسقط، ولكنّ العار ألا نستطيع النّهوض
Drug Therapy of Gout 1.
GOUT.
  URIC ACID Muthana A. Al-Shemeri.
Gout and Hyperuricaemia
Recent Advancement In Therapeutics ZURAMPIC ( LESINURAD)
Antiuricaemic drugs Dr A.W Olusanya.
Lecture 9 Musculoskeletal Disorders Gout
oral hypoglycemic agents
Munir Gharaibeh, MD, PhD, MHPE The University of Jordan
Gout and Hyperuricaemia
Drugs for Gout, osteoarthritis and osteoporosis Dr Sura Al Zoubi
Gout Scott Smith PGY-1 1/11/2018.
TREATMENT OF THE ACUTE GOUT ATTACK:
NSAIDs Epidemiology NSAIDs amounts to 3.8 of all prescriptions
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Drugs in gout.
Non opioids pain management
Presentation transcript:

Drugs in gout epidemiology Male to female ration 10:1 Prevalence of hyperuricemia 5% Prevalence of gout 0.2%

Drugs in gout ilos Describe drug and non drug treatment of gout Identify the mechanism of action of drugs used for treatment of gout Outline the stages of gout and the therapeutic objectives in each stage Study in detail the pharmacology of drugs used for treatment of gout Classify drugs used for treatment of gout

Drugs in gout What is Nephrolithiasis Tofi gout?

Over production Under excretion Uricosuric Uricostatic Anti- inflammatory Colchicine Pathophsiology

Drugs in gout Colchicine Tubulin inhibitors NSAIDs, Steroids Anti- inflammatory Uricostatic Probenecid, Sulfinpyrazone Uricosuric Allopurinol, Febuxostat

Stages of gout Treat or not to treat? Prevent recurrent attacks Terminate The attack -Prevent complications -Lower serum uric acid

Drugs in gout Treatment of gout Non- pharmacologic Pharmacologic

Non-pharmacologic Therapy Lifestyle modifications Loss of weight Smoking cessation Diet control Excercise

Treatment of acute gout ColchicineNSAIDs Acute gouty arthritis Corticosteroids

NSAIDS NSAIDs are the most commonly used first-line treatment Head-to-head studies show few differences between drugs Full doses of NSAID should be initiated immediately and tapered after resolution of symptoms Avoid NSAIDs: G-I ulcer Bleeding or perforation Renal insufficiency Heart failure Use of oral anticoagulants

steroids Corticosteroids are a good alternative where NSAID and colchicine cannot be used or in refractory cases Studies showed equal efficacy between corticosteroid and NSAIDs, with no reported side-effects with short-term use of corticosteroid In elderly people, patients with kidney or hepatic impairment, IHD, PUD, hypersensitivity to NSAIDs -Intra articularly (preferred route if one or two joints affected) -Orally -Intramuscularly or intravenously.

colchicine Alkaloid obtained from autumn crocus Minimal effect on uric acid synthesis, excretion & is not analgesic

Drugs in gout mechanism Binds to microtubules in neutrophils Inhibits inflamosomes & IL-1 production Inhibits cell division Inhibits chemotactic factors

colchicine pharmacokinetics Administered orally, rapid absorption from the GI tract Reaches peak plasma levels within 2 hours Use should be avoided in patients with a creatinine clearance of less than 50 mL/min. Recycled in the bile and is excreted unchanged in the faeces or urine

colchicine Clinical uses - Treatment of gout flares - Prophylaxis of gout flares - Treatment of Mediterranean fever Colchicine 0.6 mg twice daily (n=21) Placebo (n=22) Mean Number of Flares 1 0–33–6 † * Time Interval, Months

adrs - Diarrhea (sometimes severe) - Nausea - Vomiting - Abdominal cramps - Dehydration Bone marrow depression: nadir at 7 days - Cardiac toxicity,Arrhythmia - Vascular collapse Hepatotoxicity, Alopecia

Prevention of recurrent attack Inhibition of uric acid synthesis -Allopurinol -Febuxostat Uricosuric drugs -Probenacid -Sulfinpyrazone Mamalian Uricase

Inhibitors of uric acid synthesis Inhibit xanthine oxidase Allopurinol is metabolized by xanthine oxidase into alloxanthine which is pharmacologicaly active Include allopurinol & febuxostat

pharmacokinetics Absorption 70% Protein binding negligble,5% Oxypurinol is elminated unchaged in urine Hepatic metabolism, 70% converted to active metabolite(oxypurinol) Allopurinol Oxypurinol Xanthine Oxidase Dress Syndrome Allopurinol Hypersensitivity Syndrome Toxic Epidermal Necrolysis

allopurinol Clinical uses Management of hyperuricemia of gout Management of hyperuricemia associated with chemotherapy Prevention of recurrent calcium oxalate kidney stones Uric acid stones or nephropathy Severe tophaceous deposits (uric acid deposits in tissues) It is a drug of choice in patients with both gout & ischemic heart disease

adrs Diarrhea, nausea, abnormal liver tests Acute attacks of gout Fever, rash, toxic epidermal necrolysis,hepatotoxicity, marrow suppression, vasculitis DRESS syndrome Drug Reaction, Eosinophilia, Systemic Symptoms 20% mortality rate

Drug Interactions Inhibits metabolism of Warfarin & dicumarol Reduce the metabolism of 6-mercaptopurine and azathioprine With ampicillin : Increases frequency of skin rash

Febuxostat Oral specific xanthine oxidase inhibitor Indicated for the chronic management of hyperuricemia in patients with gout Chemically distinct from allopurinol (non purine) can be used in patients with renal disease

Metabolized in liver, mainly conjugated to glucouronic acid Given to patients who do not tolerate allopurinol 99% protein bound t½ 8hours pharmacokinetics Given orally once daily, well absorbed(85%) Febuxostat

adrs Increase number of gout attacks during the first few months of treatment Increase level of liver enzymes Nausea, Diarrhea Headache Numbness of arm or leg Febuxostat

Uricosuric drugs Mechanism Blocks tubular reabsorption of uric acid & enhances urine uric acid excretion Probenecid inhibits Urate Transporters (URAT) in the apical membrane of the proximal tubule It also inhibits organic acid transporter(OAT) →↑plasma concentration of penicilin Sulfinpyrazol inhibits URAT1 & OAT4

Probenecid moderately effective Increases risk of nephrolithiasis Not used in patients with renal disease Some drugs reduce efficacy (e.g. aspirin) Control hyperuricemia and prevent tophus formation Uricosuric drugs

adrs Exacerbation of acute attack Risk of uric acid stone GIT upset Allergic rash probenecid

Contra-indications History of nephrolithiasis Recent acute gout Existing renal disease Less effective in elderly patients

Drugs in gout sulfinpyrazone Sulfinpyrazone can aggravate peptic ulcer disease Aspirin reduces efficacy of sulfinpyrazone Sulfinpyrazone enhance the action of certain antidiabetic drugs

Recombinant mammalian uricase Pegloticase A uric acid specific enzyme which is a recombinant modified mammalian uricase enzyme Converts uric acid to allantoin Given I.V.  peak decline in uric acid level within hours

pegloticase Used for the treatment of chronic gout in adult patients refractory to conventional therapy ADRS Infusion reactions Anaphylaxis Nephrolithiasis Arthralgia, muscle spasm Gout flare